跳至主要内容
临床试验/NCT02060149
NCT02060149Unknown1 期

The Effect of Nebulization of Alkaline Solution on Treating Extensively Drug Resistant A. Baumannii Pneumonia With Cefoperazone and Sulbactam Plus Minocycline: A Multi-center Randomized Study

Xijing Hospital1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2014年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
发起方
入组人数
90
试验地点
1
主要终点
Pathogenic Clearance rate and recovery rate

研究概览

简要总结

The mortality of pneumonia with extensively drug resistant Acinetobacter baumannii (XDRAB) is still high, even if these patients received certain strong anti-infection treatment such us the combination of cefoperazone-sulbactam (C/S) and minocycline. Health airway lining fluid is mildly alkaline but airway acidification usually appears for the infection of XDRAB. The hypothesis is offered that the biologic activity of XDRAB might be inhibited if the circumstance including pH is changed. In the vitro study we observed that the inhibit effect of antibiotics on XDRAB growth was improved significantly by alkaline solution within the scope of physiology. So the aim of this clinical study is to explore the effects of nebulization of alkaline Solution on C/S plus minocycline on the pneumonia with XDRAB.

详细描述

Pneumonia patients with XDRAB are eligible for this multicenter study, do not meet the exclusion criteria and will sign the informed consent. They will received the anti-infection protocol with Cefoperazone/ sulbactam 3.0g(intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral, q12h). All enrolled patients were randomly divided into three groups according to the difference in pH value of aerosol inhalation with sodium bicarbonate solution. Group one is blank-control and patients will received usual antibiotic treatment without inhalation. The pH value in group two is 7.4 and that in group is 7.8. Each time the volume of aerosol solution is 5ml, q8h. The average course of treatment will be two weeks. Clinical indexes will be collected including vital signs, pulmonary rales, cough level, expectoration level, sputum color,blood count, arterial blood gas, biochemical parameters, chest X-ray score, APACHE II score, clinical pulmonary infection score, ECG, sputum culture, et al.The primary endpoints are pathogenic clearance rate and recovery rate. The secondary end point is adverse reaction rate.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age: 18 to 75 years old, male or female
  • The pneumonia patients met the diagnostic criteria, and clinical pulmonary infection score (CPIS) ≥ 5;
  • The sputum bacteriology detection only prompted Acinetobacter baumannii culture for pathogens concentration meets the diagnostic criteria of the Chinese hospital-acquired pneumonia diagnosis and treatment guidelines, 2002 edition of "Acinetobacter baumannii and susceptibility results show only 1 to 2 sensitive to antimicrobial drugs (polymyxin, minocycline or tegafur doxycycline);
  • Cephalosporins or tetracyclines drug treatment without a history of allergies and contraindications;
  • Be able to accept inhalation therapy.
  • Informed consent gained

排除标准

  • Refused to accept inhalation therapy
  • Renal insufficiency, creatinine clearance (Cockcroft-Gault formula) (CLcr) 15 ml / min or less;
  • Liver dysfunction, defined as Child-Pugh score B or C
  • Within one week before the start of cefoperazone sulbactam, minocycline treatment.

研究组 & 干预措施

no nebulization

Sham Comparator

Antibiotics protocol is C/S plus minocycline. That is Cefoperazone/ sulbactam 3.0g(intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral,q12h).No nebulization will given to these patients.

干预措施: C/S plus minocycline. (Drug)

no nebulization

Sham Comparator

Antibiotics protocol is C/S plus minocycline. That is Cefoperazone/ sulbactam 3.0g(intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral,q12h).No nebulization will given to these patients.

干预措施: No nebulization (Drug)

nebulization with pH 7.4 solution

Active Comparator

Patients will received the same antibiotics protocol with C/S plus minocycline and nebulization with pH 7.4 solution(Each time the volume of aerosol solution is 5ml, q8h).

干预措施: C/S plus minocycline. (Drug)

nebulization with pH 7.4 solution

Active Comparator

Patients will received the same antibiotics protocol with C/S plus minocycline and nebulization with pH 7.4 solution(Each time the volume of aerosol solution is 5ml, q8h).

干预措施: nebulization with pH 7.4 solution (Drug)

nebulization with pH 7.8 solution

Experimental

Patients will received the same antibiotics protocol with C/S plus minocycline and nebulization with pH 7.8 solution(Each time the volume of aerosol solution is 5ml, q8h).

干预措施: C/S plus minocycline. (Drug)

nebulization with pH 7.8 solution

Experimental

Patients will received the same antibiotics protocol with C/S plus minocycline and nebulization with pH 7.8 solution(Each time the volume of aerosol solution is 5ml, q8h).

干预措施: nebulization with pH 7.8 solution (Drug)

结局指标

主要结局

Pathogenic Clearance rate and recovery rate

时间窗: one treatment course for about two weeks

次要结局

  • adverse reaction rate(one treatment course for about two weeks)

研究者

发起方
Xijing Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

songlq

vice director of department of respiratory and criticle care medicine

Xijing Hospital

研究点 (1)

Loading locations...

相似试验